Literature DB >> 2765536

Anthracycline incorporation in human lymphocytes. Kinetics of uptake and nuclear concentration.

J Tarasiuk1, F Frézard, A Garnier-Suillerot, L Gattegno.   

Abstract

Fluorescence emission spectra from anthracycline-treated cells suspended in buffer have been studied. The kinetics of uptake and the nuclear concentration of anthracyclines in human lymphocytes have thus been determined using the fluorescence properties of these drugs. Four anthracyclines have been used: adriamycin (ADR), 4'-O-tetrahydropyranyl-adriamycin (THP-ADR), carminomycin (CAR) and aclacinomycin A (ACM). We have shown that no quenching of the drug fluorescence is obtained through interaction of the drugs with the various components of the cell except the nucleus. No quenching is observed with cells lacking nucleus such as platelets and erythrocytes. Quenching of drug fluorescence occurs when drugs intercalate between base pairs of DNA only. This allows rapid determination of the amount of drug intercalated between nuclear base pairs in the steady state. We have thus estimated that one molecule of drug can bind for every 10, 8.3, 10 and 6.7 DNA base pairs in the case of ADR, THP-ADR, ACM and CAR, respectively. The kinetics of drug incorporation into the nucleus, once the cells have been solubilized with triton X-100, is very fast for the four drugs. However, the kinetics of drug uptake by the intacts cells strongly depends on the nature of the drug. When 10(9) cells/l are incubated with 1 microM drug, 50% of the final nuclear concentration is reached within 97 min, 3.2 min, 3.0 min and 1.2 min in the case of ADR, THP-ADR, CAR and ACM, respectively. The kinetics directly correlates with the polarity of the molecule.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2765536     DOI: 10.1016/0167-4889(89)90038-4

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  13 in total

1.  A new approach to the estimation of functional activity of ABC-transporters regulating intracellular distribution of anticancer drugs using flow cytometry.

Authors:  T A Bogush; A B Ravcheeva; A V Konukhova; E A Bogush; A Y Baryshnikov; M I Davydov
Journal:  Dokl Biochem Biophys       Date:  2005 Nov-Dec       Impact factor: 0.788

2.  Extracellular concentration of anticancer drugs that regulates their intracellular distribution and binding to DNA in cells with multidrug resistant phenotype.

Authors:  T A Bogush; A B Ravcheeva; E A Bogush; A V Konukhova; K E Kuz'mina; A Y Baryshnikov; M I Davydov
Journal:  Dokl Biochem Biophys       Date:  2006 Sep-Oct       Impact factor: 0.788

3.  Anthrapyridones, a novel group of antitumour non-cross resistant anthraquinone analogues. Synthesis and molecular basis of the cytotoxic activity towards K562/DOX cells.

Authors:  J Tarasiuk; B Stefańska; I Plodzich; K Tkaczyk-Gobis; O Seksek; S Martelli; A Garnier-Suillerot; E Borowski
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

4.  Laser flow cytometric studies on the intracellular accumulation of anthracyclines when combined with heat.

Authors:  Y Sakaguchi; Y Maehara; S Inutsuka; I Takahashi; M Yoshida; Y Emi; H Baba; K Sugimachi
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

5.  Predicting drug pharmacokinetics and effect in vascularized tumors using computer simulation.

Authors:  John P Sinek; Sandeep Sanga; Xiaoming Zheng; Hermann B Frieboes; Mauro Ferrari; Vittorio Cristini
Journal:  J Math Biol       Date:  2008-09-10       Impact factor: 2.259

6.  Direct evaluation of intracellular accumulation of free and polymer-bound anthracyclines.

Authors:  T Bogush; G Smirnova; I Shubina; A Syrkin; J Robert
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

7.  A Flow Cytometric Clonogenic Assay Reveals the Single-Cell Potency of Doxorubicin.

Authors:  Katie F Maass; Chethana Kulkarni; Mohiuddin A Quadir; Paula T Hammond; Alison M Betts; Karl Dane Wittrup
Journal:  J Pharm Sci       Date:  2015-09-07       Impact factor: 3.534

8.  Multiscale kinetic modeling of liposomal Doxorubicin delivery quantifies the role of tumor and drug-specific parameters in local delivery to tumors.

Authors:  B S Hendriks; J G Reynolds; S G Klinz; E Geretti; H Lee; S C Leonard; D F Gaddy; C W Espelin; U B Nielsen; T J Wickham
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2012-11-21

9.  Early multidrug resistance, defined by changes in intracellular doxorubicin distribution, independent of P-glycoprotein.

Authors:  G J Schuurhuis; H J Broxterman; J H de Lange; H M Pinedo; T H van Heijningen; C M Kuiper; G L Scheffer; R J Scheper; C K van Kalken; J P Baak
Journal:  Br J Cancer       Date:  1991-11       Impact factor: 7.640

10.  Changes in subcellular doxorubicin distribution and cellular accumulation alone can largely account for doxorubicin resistance in SW-1573 lung cancer and MCF-7 breast cancer multidrug resistant tumour cells.

Authors:  G J Schuurhuis; T H van Heijningen; A Cervantes; H M Pinedo; J H de Lange; H G Keizer; H J Broxterman; J P Baak; J Lankelma
Journal:  Br J Cancer       Date:  1993-11       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.